Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ELOXX PHARMACEUTICALS INC (ELOX) Stock Price & Overview
NASDAQ:ELOX • US29014R2022
Current stock price
3.82 USD
-0.23 (-5.68%)
At close:
2.8 USD
-1.02 (-26.7%)
After Hours:
The current stock price of ELOX is 3.82 USD. Today ELOX is down by -5.68%. In the past month the price decreased by -35.03%. In the past year, price decreased by -40.31%.
ELOX Key Statistics
52-Week Range1.6959 - 10.9
Current ELOX stock price positioned within its 52-week range.
1-Month Range3.79 - 5.99
Current ELOX stock price positioned within its 1-month range.
- Market Cap
- 10.696M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.36
- Dividend Yield
- N/A
ELOX Stock Performance
Today
-5.68%
1 Week
-11.57%
1 Month
-35.03%
3 Months
-52.07%
Longer-term
6 Months -50.90%
1 Year -40.31%
2 Years -93.03%
3 Years -96.23%
5 Years -99.21%
10 Years N/A
ELOX Stock Chart
ELOX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ELOX. When comparing the yearly performance of all stocks, ELOX is a bad performer in the overall market: 89.85% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ELOX Earnings
Next Earnings DateNov 8, 2023
Last Earnings DateAug 11, 2023
PeriodQ2 / 2023
EPS Reported-$1.96
Revenue Reported
EPS Surprise -24.78%
Revenue Surprise %
ELOX Forecast & Estimates
7 analysts have analysed ELOX and the average price target is 61.2 USD. This implies a price increase of 1502.09% is expected in the next year compared to the current price of 3.82.
Analysts
Analysts85.71
Price Target61.2 (1502.09%)
EPS Next Y51.16%
Revenue Next YearN/A
ELOX Financial Highlights
Over the last trailing twelve months ELOX reported a non-GAAP Earnings per Share(EPS) of -11.36. The EPS increased by 43.2% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-24.40M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -407.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%59.17%
Sales Q2Q%N/A
EPS 1Y (TTM)43.2%
Revenue 1Y (TTM)N/A
ELOX Ownership
Ownership
Inst Owners0%
Shares2.80M
Float2.66M
Ins Owners156.5%
Short Float %0.08%
Short Ratio0.04
ELOX Industry Overview
ELOX operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
ELOX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELOX
Company Profile
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Company Info
IPO: 2012-11-23
ELOXX PHARMACEUTICALS INC
480 Arsenal Way, Suite 130
Watertown MASSACHUSETTS 02451 US
CEO: Gregory C. Williams
Employees: 18
Phone: 17815775300.0
ELOXX PHARMACEUTICALS INC / ELOX FAQ
What does ELOXX PHARMACEUTICALS INC do?
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Can you provide the latest stock price for ELOXX PHARMACEUTICALS INC?
The current stock price of ELOX is 3.82 USD. The price decreased by -5.68% in the last trading session.
Does ELOX stock pay dividends?
ELOX does not pay a dividend.
How is the ChartMill rating for ELOXX PHARMACEUTICALS INC?
ELOX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is ELOXX PHARMACEUTICALS INC (ELOX) stock traded?
ELOX stock is listed on the Nasdaq exchange.
How is the valuation of ELOXX PHARMACEUTICALS INC (ELOX) based on its PE ratio?
ELOXX PHARMACEUTICALS INC (ELOX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.36).
Would investing in ELOXX PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELOX.